The Clinical Trials Network is pleased to announce the addition of a new participating center for its on-going trial, the Study of Fluoxetine in Autism (SOFIA): the Institute for Behavioral Medicine
in Smyrna, GA. The study will include more than 100 children and adolescents (ages 5-17) with autism to confirm the effectiveness of Neuropharm's custom-designed product NPL-2008, a proprietary preparation of fluoxetine, in reducing certain core symptoms of autism. This new formulation will feature autism-specific doses in a melt-in-the-mouth formulation designed specifically for those with autism.
To learn more about the study, other participating sites and how to participate please email:
Or click on the link to our information page: